Key Takeaway: Aardvark Therapeutics reported its second quarter 2026 financial results, highlighting the assessment of unblinded Phase 3 HERO and OLE data for ARD-101 in Prader-Willi Syndrome (PWS). The company is in active discussions with the FDA regarding the resolution of a clinical hold on the ARD-101 program. Aardvark also reported a cash position of $73.9 million.
Market Sentiment Analysis
POSITIVE FACTORS
Aardvark Therapeutics is assessing promising Phase 3 data for ARD-101.
Active discussions with the FDA indicate progress in resolving clinical hold.
The company has a solid cash position of $73.9 million.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+127%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
ARD-101
Phase 2 · Bariatric Surgery
Full Press Release Details
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program $73.9 million in cash, cash equivalents and
Frequently Asked Questions
What are the key financial results for Aardvark in Q2 2026?
Aardvark reported $73.9 million in cash and cash equivalents.
What is the status of the ARD-101 program?
The company is assessing Phase 3 data and discussing a clinical hold with the FDA.
What condition is ARD-101 targeting?
ARD-101 is being developed for Prader-Willi Syndrome (PWS).